ImmunityBio (IBRX) Receivables (2014 - 2026)

ImmunityBio (IBRX) has reported Receivables for 8 consecutive years, with $43.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 153.14% year-over-year to $43.3 million; the TTM figure through Mar 2026 stood at $43.3 million (up 153.14% YoY), while the FY2025 annual figure was $42.6 million, up 1564.73% from the prior year.
• Receivables improved to $43.3 million in Q1 2026 per IBRX's latest filing, from $42.6 million in the prior quarter.
• Across five years, Receivables topped out at $43.3 million in Q1 2026 and bottomed at $2.0 million in Q4 2023.
• Historically, Receivables has averaged $14.1 million across 5 years, with a median of $3.6 million in 2023.
• Annual changes were most pronounced in 2023 — Receivables slumped 36.71% — and 2025, when it jumped 1564.73%.
• ImmunityBio's Receivables stood at $3.2 million in 2022, then plunged by 36.71% to $2.0 million in 2023, then gained by 26.8% to $2.6 million in 2024, then surged by 1564.73% to $42.6 million in 2025, then climbed by 1.54% to $43.3 million in 2026.
• Business Quant data shows IBRX's Receivables at $43.3 million in Q1 2026, $42.6 million in Q4 2025, and $33.7 million in Q3 2025.